Incyte Corporation — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022; comparisons are with Q1 2021 unless noted. Incyte is a biopharmaceutical company with commercial products and a drug-development pipeline, reported as one operating segment. Figures below are in U.S. dollars; financial statement amounts are in millions unless otherwise stated.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Total revenue | $733.2 | $604.7 | +21.3% |
| Operating income | $116.5 | $98.8 | +17.9% |
| Net income | $38.0 | $53.5 | -29.0% |
| Diluted EPS | $0.17 | $0.24 | Lower |
| Operating cash flow | $215.7 | $206.1 | +4.7% |
| Capital expenditures | $17.0 | $48.1 | Lower |
- Product revenue was $605.8 million, up 20.0%; royalties were $122.4 million, up 22.5%; milestone and contract revenue was $5.0 million, versus none. JAKAFI revenue was $544.5 million, approximately 74% of total revenue.
- Cost of product revenue was $42.6 million. Product gross margin, calculated as revenue less cost of product revenue, was approximately 94.2%, versus 95.2% in Q1 2021. Operating margin was approximately 15.9%, versus 16.3%.
- Research and development expense rose to $353.4 million from $306.9 million; selling, general and administrative expense rose to $209.6 million from $153.8 million. Management attributed increases principally to late-stage development investment and expansion of the dermatology commercial organization supporting OPZELURA.
- Net income was reduced by a $46.6 million unrealized loss on long-term investments, compared with a $27.7 million loss in Q1 2021. Income tax expense was $32.5 million, versus $15.8 million; the filing attributes the higher 2022 expense to the release of a valuation allowance against most U.S. deferred tax assets at year-end 2021.
- At March 31, cash and cash equivalents were $2.257 billion, current marketable securities $287.4 million, and long-term investments $174.7 million. Current assets were $3.288 billion against current liabilities of $886.2 million. The company reported $2.5 billion of cash, cash equivalents and marketable securities.
- Total liabilities were $1.191 billion, including finance lease liabilities of $34.2 million and acquisition-related contingent consideration of $242.0 million. No borrowings were outstanding under the $500 million revolving credit facility. The company reported compliance with its covenants.
Material changes and notable items
- Revenue growth reflected higher JAKAFI sales, royalties from OLUMIANT and JAKAVI, and launches or ramp-up of newer products. OPZELURA, launched in October 2021, generated $12.8 million; MINJUVI generated $4.5 million. PEMAZYRE revenue was $18.0 million, including a $5.0 million milestone following approval in China.
- Management attributed the $78.8 million year-over-year increase in JAKAFI sales to volume ($43.3 million) and price ($35.5 million). The filing notes that customer purchasing patterns and inventory building ahead of price increases can cause quarterly fluctuations.
- Long-term investments in publicly traded collaborators generated a total $46.6 million unrealized loss, recorded in earnings. Their combined balance declined from $221.3 million at year-end 2021 to $174.7 million at March 31, 2022.
- In January 2022, Incyte opted out of further development of Merus’s MCLA-145. In January, it also withdrew the parsaclisib NDA for three lymphoma indications after determining confirmatory studies could not be completed within a reasonable period to support accelerated approval.
Outlook, risks and contingencies
- The filing provides no specific revenue or earnings guidance. Management stated that operating cash flow, cash and investments, and the available revolving facility should meet capital needs for the foreseeable future.
- Incyte expected its large-molecule production facility in Yverdon, Switzerland, to receive GMP approval in the second half of 2022. Facility timing and regulatory approval remain uncertain.
- The FDA extended review of the vitiligo application for ruxolitinib cream; the stated PDUFA target action date was July 18, 2022. The filing describes ongoing development across oncology, hematology and dermatology, with clinical, regulatory and commercial outcomes subject to uncertainty.
- Key business risks include reliance on JAKAFI, reimbursement and pricing pressure, competition and potential generic entry, product safety and regulatory requirements, clinical-trial failure or delays, reliance on third-party manufacturers and collaborators, and concentration in specialty pharmacies, wholesalers and customers.
- The company cited possible disruption to clinical trials and supply chains from COVID-19 and Russia’s invasion of Ukraine; it had limited clinical-trial activity in Ukraine and Russia. It also warned that collaborator equity investments may continue to fluctuate in value.
- Product inventory totaled $70.8 million, including $35.4 million classified as non-current. Approximately $69.9 million of pre-commercialization product costs remained in inventory; Incyte expected to sell that inventory over approximately 31 months, reducing average unit costs reflected in product revenue.
- Contingent consideration is a Level 3 fair-value liability, measured using projected ICLUSIG royalties and other assumptions. The filing also describes potential future milestone and royalty payments under collaboration agreements and ordinary-course legal matters; it does not identify a specific material pending contingency amount beyond the disclosed balances.
Important facts for investors to verify
- Whether JAKAFI sales growth and product diversification can offset its substantial share of revenue, and how OPZELURA’s launch and reimbursement develop.
- Whether the $46.6 million investment-related loss is temporary or signals continued volatility in collaborator investments and earnings.
- Progress and regulatory outcomes for the vitiligo application, the Yverdon facility, and the company’s major late-stage clinical programs.
- Exposure to pricing, rebates, and customer concentration: five customers represented 65% of Q1 product revenue, while the filing identifies significant specialty-pharmacy and wholesaler dependence.
- Changes in contingent consideration, collaboration commitments, inventory recoverability, and cash needs as development and commercialization spending continues.